U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H26O3
Molecular Weight 326.4293
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 4
Charge 0

SHOW SMILES / InChI
Structure of ACITRETIN

SMILES

COC1=C(C)C(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1

InChI

InChIKey=IHUNBGSDBOWDMA-AQFIFDHZSA-N
InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21720660

Acitretin is all-Trans-9-(4-methoxy-2, 3, 6¬ trimethylphenyl)-three, 7-dimethyl-2, 4, 6, 8-nonatetraenoic acid. It is a metabolite of exterminate and is related to both retinoic acid and retinol (vitamin A). It is taken orally, and is typically used for psoriasis. The mechanism of action of is unknown. However it is believed to work by targeting specific receptors (retinoid receptors such as RXR and RAR) in the skin, which help normalize the growth cycle of skin cells. Studies on nuclear retinoic acid receptors have shown that acitretin activates all 3 receptor subtypes (RAR-alpha, -beta, and -gamma) without measurable receptor binding; this paradox remains unexplained.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SORIATANE

Approved Use

Acitretin Capsules USP are indicated for the treatment of severe psoriasis in adults. Because of significant adverse effects associated with their use, Acitretin Capsules USP should be prescribed only by those knowledgeable in the systemic use of retinoids. In females of reproductive potential, Acitretin Capsules USP should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments (see boxed CONTRAINDICATIONS AND WARNINGS — Acitretin Capsules USP can cause severe birth defects). Most patients experience relapse of psoriasis after discontinuing therapy. Subsequent courses, when clinically indicated, have produced efficacy results similar to the initial course of therapy.

Launch Date

8.4646081E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
416 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACITRETIN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: MALE
food status: FED
416 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACITRETIN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2249 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACITRETIN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.8 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACITRETIN plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: MALE
food status: FED
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effects of short-term oral acitretin therapy on peripheral nerve function: a prospective neurological and neurophysiological study.
2001 Nov-Dec
Sensorimotor polyneuropathy after a three-month oral acitretin therapy.
2002 Nov-Dec
Papillon-Lefèvre syndrome treated with acitretin.
2005 Aug
A woman with sudden bilateral sensorineural hearing loss after treatment psoriasis with acitretin.
2005 Jun
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.
2006 Feb
Acitretin and sixth nerve palsy.
2007 Oct
Acitretin induces apoptosis through CD95 signalling pathway in human cutaneous squamous cell carcinoma cell line SCL-1.
2009 Sep
Patents

Sample Use Guides

SORIATANE (acitretin capsules) should be initiated at 25 to 50 mg per day, given as a single dose with the main meal. Maintenance doses of 25 to 50 mg per day may be given dependent upon an individual patient’s response to initial treatment. Relapses may be treated as outlined for initial therapy.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Acitretin plays an inhibitory role in the tumor cell growth and induces the cell apoptosis in A431 cells. The regulation of the Jak/STAT3 signaling pathway may play an important role in inducing growth inhibition and apoptosis by Acitretin in A431 cells.
A431 (epidermoid carcinoma cell lines) were treated with Acitretin at the concentration of 10(-5)mol/L in different time intervals
Name Type Language
ACITRETIN
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
ACITRETINE
Common Name English
ACITRETIN [EP MONOGRAPH]
Common Name English
ACITRETIN [MI]
Common Name English
ACITRETIN [USP-RS]
Common Name English
ACITRETIN [USAN]
Common Name English
ACITRETIN [USP IMPURITY]
Common Name English
NEOTIGASON
Common Name English
ETRETIN
Common Name English
9-(4-METHOXY-2,3,6-TRIMETHYLPHENYL)-3,7-DIMETHYL-2,4,6,8-NONATETRAENOIC ACID
Systematic Name English
acitretin [INN]
Common Name English
ACITRETIN [USP MONOGRAPH]
Common Name English
ACITRETIN [ORANGE BOOK]
Common Name English
RO 10-1670
Code English
ACITRETIN [MART.]
Common Name English
2,4,6,8-NONATETRAENOIC ACID, 9-(4-METHOXY-2,3,6-TRIMETHYLPHENYL)-3,7-DIMETHYL-, (ALL-E)-
Common Name English
RO-10-1670/000
Code English
SORIATANE
Brand Name English
RO 10-1670/000
Code English
ACITRETIN [VANDF]
Common Name English
ACITRETIN [HSDB]
Common Name English
Acitretin [WHO-DD]
Common Name English
(all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid
Common Name English
Classification Tree Code System Code
NDF-RT N0000007700
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
NDF-RT N0000175607
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
NDF-RT N0000007700
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
WHO-ATC D05BB02
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
NDF-RT N0000007700
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
WHO-VATC QD05BB02
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
NDF-RT N0000007700
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
NCI_THESAURUS C804
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
LIVERTOX NBK548784
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
NDF-RT N0000007700
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
Code System Code Type Description
CHEBI
50173
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
RS_ITEM_NUM
1011007
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
PUBCHEM
5284513
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
DRUG BANK
DB00459
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
RXCUI
16818
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY RxNorm
LACTMED
Acitretin
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
USAN
X-94
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
ChEMBL
CHEMBL1131
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
INN
5530
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
MESH
D017255
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
SMS_ID
100000084604
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
MERCK INDEX
M1373
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY Merck Index
EPA CompTox
DTXSID6022553
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
DRUG CENTRAL
78
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
WIKIPEDIA
ACITRETIN
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
FDA UNII
LCH760E9T7
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
ECHA (EC/EINECS)
259-474-4
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
HSDB
7187
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
NCI_THESAURUS
C985
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
DAILYMED
LCH760E9T7
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
IUPHAR
7598
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
EVMPD
SUB05240MIG
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY
CAS
55079-83-9
Created by admin on Wed Jul 05 22:34:59 UTC 2023 , Edited by admin on Wed Jul 05 22:34:59 UTC 2023
PRIMARY